Protagonist Therapeutics Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
Protagonist Therapeutics has a total shareholder equity of $541.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $614.6M and $73.3M respectively. Protagonist Therapeutics's EBIT is $152.2M making its interest coverage ratio -7.5. It has cash and short-term investments of $564.0M.
Wichtige Informationen
0%
Verhältnis von Schulden zu Eigenkapital
US$0
Verschuldung
| Zinsdeckungsgrad | -7.5x |
| Bargeld | US$564.00m |
| Eigenkapital | US$541.32m |
| Gesamtverbindlichkeiten | US$73.31m |
| Gesamtvermögen | US$614.63m |
Jüngste Berichte zur Finanzlage
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Recent updates
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
Oct 16Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: PTGX's short term assets ($570.9M) exceed its short term liabilities ($41.6M).
Langfristige Verbindlichkeiten: PTGX's short term assets ($570.9M) exceed its long term liabilities ($31.7M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: PTGX is debt free.
Schulden abbauen: PTGX had no debt 5 years ago.
Schuldendeckung: PTGX has no debt, therefore it does not need to be covered by operating cash flow.
Zinsdeckung: PTGX has no debt, therefore coverage of interest payments is not a concern.